Publication | Closed Access
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
166
Citations
0
References
2018
Year
Drug SafetyPivotal TrialEngineeringClinical TherapeuticR/r Aggressive NhlPharmacologyClinical TrialsDefined CompositionTranslational ResearchPharmacotherapyTranscend Nhl 001Precise DoseDrug TrialLisocabtagene MaraleucelMedicineCell BiologyBiomolecular Engineering
7505Background: Lisocabtagene maraleucel (liso-cel; JCAR017) is a CD19-directed 4-1BB CAR T cell product administered in defined composition at a precise dose of CD8 and CD4 CAR T cells. A multicen...